Sensory and affective pain descriptors respond differentially to pharmacological interventions in neuropathic conditions

Clinical Journal of Pain

Volumn 29, Issue 2, 2013, Pages 124-131

  Gilron, Ian ^a   Tu, Dongsheng ^b   Holden, Ronald R ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Jeffery Hall Queen's University   (Canada)

Author keywords

clinical trials; neuropathic pain; pain assessment; pain descriptor; Pain quality; psychometric evaluation

Indexed keywords

GABAPENTIN; LORAZEPAM; MORPHINE; PLACEBO;

AFFECT; ARTICLE; CLINICAL EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; MCGILL PAIN QUESTIONNAIRE; NEUROPATHIC PAIN; PAIN; PREDICTION; PRIORITY JOURNAL; SELF REPORT; SENSORY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMINES; ANALGESICS; CASE-CONTROL STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LINEAR MODELS; MALE; MORPHINE; NEURALGIA; PAIN MEASUREMENT; PAIN PERCEPTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84872071528     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31824ce65c     Document Type: Article

References (43)

1. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 suppl):S3-14.
2. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265-275.
3. Dworkin RH, Turk DC, Katz NP, et al. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain. 2011;152(3 suppl):S107-S115.
4. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
5. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. . 1998; 5:209-227.
6. Maier C, Baron R, Tö lle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439-450.
7. Baron R, Tö lle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009;146:34-40.
8. Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain. 1998;77: 227-229.
9. Woolf CJ, MaxMB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology. 2001;95:241-249.
10. Finnerup NB, Jensen TS. Mechanisms of disease: mechanismbased classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol. 2006;2:107-115.
11. Max MB. Towards physiologically based treatment of patients with neuropathic pain. Pain. 1990;42:131-137.
12. Max MB. Is mechanism-based pain treatment attainable? Clinical trial issues. J Pain. 2000;1(3 suppl):2-9.
13. Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med. 2010;16:1241-1247.
14. Gilron I, Attal N, Bouhassira D, et al. Neuropathic pain assessment. In: Turk DC, Melzack R, eds. Handbook of Pain Assessment. 3rd ed. New York: Guilford Press; 2010:326-353.
15. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14-27.
16. Jensen MP. Using pain quality assessment measures for selecting analgesic agents. Clin J Pain. 2006;22(1 suppl):S9-13.
17. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
18. Melzack R. The Short-Form McGill Pain Questionnaire. Pain. 1987;30:191-197.
19. Attal N, Bouhassira D, Baron R, et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain. 2011;15:441-443.
20. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
21. Gould EM, Jensen MP, Victor TW, et al. The pain quality response profile of oxymorphone extended release in the treatment of low back pain. Clin J Pain. 2009;25:116-122.
22. Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain. 2009;25:286-292.
23. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293-302.
24. Nikolajsen L, Gottrup H, Kristensen AG, et al. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg. 2000;91: 960-966.
25. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274-283.
26. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260.
27. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain. 2007;127:199-203.
28. Dworkin RH, Jensen MP, Gammaitoni AR, et al. Symptom profiles differ in patients with neuropathic versus nonneuropathic pain. J Pain. 2007;8:118-126.
29. Hansen N, Klein T, Magerl W, et al. Psychophysical evidence for long-term potentiation of C-fiber and Adelta-fiber pathways in humans by analysis of pain descriptors. J Neurophysiol. 2007;97:2559-2563.
30. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332-338.
31. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257.
32. Jensen MP, Gammaitoni AR, Olaleye DO, et al. The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain. 2006;7:823-832.
33. Attal N, Rouaud J, Brasseur L, et al. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004;62:218-225.
34. Edwards RR, Haythornthwaite JA, Tella P, et al. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology. 2006;104:1243-1248.
35. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.
36. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23: 129-138.
37. Ware JE, Snow KK, Kosinski MA, et al. SF-36 Health Survey Manual and Interpretation, Guide. Boston: Nimrod Press; 1997.
38. Beck AT, Steer RA. Beck Depression Inventory, manual. San Antonio, TX, : Psychological Corporation; 1993.
39. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in, patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
40. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for, the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-1842.
41. Agarwal S, Polydefkis M, Block B, et al. Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. Pain Med. 2007;8:554-562.
42. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
43. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain. 2010;150:12-16.